<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although numerous options are available for patients with recurrent low-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), responses are rarely durable </plain></SENT>
<SENT sid="1" pm="."><plain>We previously conducted a phase I trial of fludarabine and paclitaxel in the treatment of recurrent low-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The present phase II study was performed to determine the activity of fludarabine and paclitaxel in patients with recurrent low-grade NHL </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with histologically confirmed recurrent low-grade NHL were treated with fludarabine 20 mg/m2/day intravenously (i.v.) on days 1-5 plus paclitaxel 50 mg/m2 given by i.v. continuous infusion over 72 h starting on day 1 </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment was repeated at 4-week intervals for a maximum of six courses </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-eight evaluable patients were entered into this phase II trial </plain></SENT>
<SENT sid="6" pm="."><plain>The median age was 53 years and the median performance status (Zubrod) was 1 </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-two (78%) patients had grade 1 or 2 follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and six patients (21%) had small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The median number of prior chemotherapy regimens was 1 (range, 1-3) </plain></SENT>
<SENT sid="9" pm="."><plain>Objective responses occurred in 16 patients (57%); nine patients (32%) achieved a complete remission with a median duration of 32 months (range 4-84+ months), and seven patients (25%) had a partial remission </plain></SENT>
<SENT sid="10" pm="."><plain>Grade 3 and 4 toxicities included <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (72%), neutropenic <z:hpo ids='HP_0001945'>fever</z:hpo> (34%), <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (13%), mucositis (7%), and <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (3%) </plain></SENT>
<SENT sid="11" pm="."><plain>The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL </plain></SENT>
</text></document>